June 2026
Methodist Healthcare Ministries chief executive Jaime Wesolowski and Blue Zones founder Dan Buettner argue that South Texas can become a large-scale test of longevity work built around prevention rather than clinical care. In a session at Aspen Ideas: Health, they described a potential seven-city Rio Grande Valley effort that would use local institutions, city policy, food environments, walkability, faith groups and social networks to make healthier daily choices easier for roughly 1mn people. Their case is that the region’s severe chronic-disease burdens coexist with cultural assets — family, faith, connection and traditional foodways — that could be amplified rather than replaced.
Futurist Jamie Metzl, author of Superconvergence, argues that AI, genetics, biotechnology and related fields are no longer separate revolutions but a compounding system giving humans the ability to read, write and alter life itself. In his Aspen Ideas: Health talk, Metzl says those powers could extend healthier lives and remake medicine, food, materials and research, but only if institutions and individuals put governance and values ahead of technological capability.
At Aspen Ideas: Health, trauma researcher Rachel Yehuda and federal health adviser Matthew Zorn argued that the central question for psychedelic medicine is not simply whether compounds such as MDMA and psilocybin can win approval, but what kind of treatment they would become. Yehuda cautioned that the molecule alone is not the intervention: preparation, setting, trained clinicians and integration may be essential to both safety and benefit. Zorn said federal momentum could move the field toward medical use, but approval would leave unresolved the harder problems of delivery, coverage, evidence and access.
Alicia Jackson of ARPA-H and Jamie Justice of XPRIZE argue that longevity science should be judged less by promises of longer life than by whether it can compress the years people spend in decline. In a discussion moderated by Latif Nasser, they describe two funding models — government milestone funding and outcome-based prizes — meant to force evidence around healthspan interventions before hype or institutional inertia takes over. Both frame the central bet as restoring measurable function in areas such as muscle, cognition and immunity, while testing even radical ideas against predefined standards.
NVIDIA presents cuPhoton as a GPU-accelerated pipeline meant to remove the processing bottleneck behind Rubin Observatory’s nightly 20TB sky surveys. The company argues that by accelerating image loading, high-performance analysis, AI-assisted signal detection and searchable storage across multi-GPU, multi-node systems, cuPhoton can turn workflows that once took months into minutes. Its stated claim is a 14,900-fold speedup in image loading and reading and up to an 8,400-fold acceleration in processing and analysis.
Wellstar Health System and its rural partners argue that the rural care crisis cannot be solved by transferring more patients to urban hospitals or acquiring local facilities. They describe a Digital Care Network that gives rural emergency, inpatient, and ICU teams 24/7 specialist support by telemedicine, allowing many patients who would previously have been transferred to stay in their local hospital. Matt Lyon of Augusta University’s Medical College of Georgia said the mature model has reversed the expected pattern, with about 70% of comparable patients kept locally rather than sent out.
Brynn Putnam, founder and CEO of Board, argues that video games can become more social by moving the screen from individual devices to a shared tabletop. In a This Week in Startups interview, she describes Board as a $399 “face-to-face gaming console” that uses a 24-inch touchscreen and physical pieces to combine the interactivity of video games with the accessibility of family board games. The broader case is that category-creating hardware has to make the experience legible before the market is obvious.
At Aspen Ideas: Health, Francis Collins moderated three teenage researchers whose work targets gaps between biological evidence and clinical care. Maya Hammoud described an organoid model linking ASXL3 loss to neuron deficits in neurodevelopmental disorders; Claire Jiang presented a cell model intended to make juvenile idiopathic arthritis easier to study; and Edward Kang argued that AI analysis of retinal images could help refer children for autism or ADHD evaluation earlier, without replacing behavioral diagnosis.
At Aspen Ideas: Health, Jeremy Faust, Jane Golden, Tiffany Ortiz, and David Leventhal made the case that art is increasingly being treated as a health intervention rather than a cultural amenity. Drawing on mural-making in behavioral health, lullaby-writing for stressed parents, and dance for people with Parkinson’s, they argued that artistic practice can change movement, bonding, stress regulation, identity, and community ownership. The discussion also turned on evidence: how to measure these effects rigorously enough for clinicians, insurers, funders, and public systems without reducing the work to a simple dose or stripping it of meaning.
A panel at Aspen Ideas: Health argued that GLP-1 drugs are becoming an economic force well beyond pharmaceuticals, changing what households buy while forcing employers, insurers, public programs, pharmacy benefit managers and manufacturers to rethink access to expensive chronic-care medicines. PwC’s Ali Furman pointed to spending shifts in groceries, restaurants, apparel and travel; Eli Lilly’s Laura Steele described new direct-to-consumer and employer channels built around demand; and economist Kosali Simon cautioned that the benefits may not show up simply as lower medical costs.
Cerebras chief executive Andrew Feldman told Bloomberg that investors are misreading the company’s post-earnings margin pressure, arguing it reflects a deliberate move to rent back sold equipment to meet demand rather than a weakening business. His broader case is that Cerebras is ahead of plan, avoids several AI chip supply bottlenecks through its architecture, and now faces a different constraint: the speed at which usable data-center capacity can be built.
Andreessen Horowitz general partner David George argues that SpaceX’s path to AI computing in orbit depends less on proving new physics than on executing rapid Starship reusability. In a Bloomberg Technology interview with Ed Ludlow, George said lower-cost, repeatable transport to orbit could make space-based GPU capacity an incremental answer to tightening constraints on terrestrial AI data centers, while framing Elon Musk’s role as central to a16z’s long-term investment case.
Flows Agent is presented as a conversational workspace for turning a creative prompt into an editable multimodal media workflow. The source argues that its value is not just generating a single video, image, or audio asset, but assembling a structured flow of voice, image, video, and sound nodes that users can revise through natural-language prompts, replace with uploaded assets, and later customize or export.
Arthur Brooks argues that feeling stuck is often a meaning problem with three separate parts: coherence, purpose and significance. In a conversation with Chris Williamson, Brooks says people need an answer for why life is unfolding as it is, a direction that lets them experience progress, and a sense that their life matters without having to earn love or public approval.
Toy designer Cas Holman argues that play is not a break from serious work but a designed condition for learning, collaboration, and problem-solving. In an Aspen Ideas: Health workshop built around her Rigamajig construction system, Holman makes the case for open-ended play: environments with enough constraint to prompt action and enough ambiguity to let children and adults discover what they are making, rather than execute a prescribed outcome.
At Aspen Ideas: Health, emergency physician and musician Jeremy Faust joined Patrick and Daniel Lazour to make the case behind their cancer musical Night Side Songs: communal singing can turn private illness into shared care. The Lazours argue that patients, caregivers, and clinicians do not need forced optimism or perfect language so much as practices that help them remain present with one another through treatment, grief, remission, and ordinary life.
Sam Parr and Shaan Puri use this My First Million discussion to argue that some of the best businesses are built around value that conventional analysis misses: surplus deliberately passed to customers, or trust supplied to markets that cannot price goods on their own. Puri frames Nick Sleep’s investments in Costco, Amazon and Berkshire as a lesson in shared scale economies, while his analysis of PSA casts authentication as a lucrative tax on collectible markets. Parr extends the same pattern through examples from cheap media, consumer products, billionaire money habits and niche collectibles, where strange or low-status behaviors can become durable markets once scale or trust catches up.
Former NIH director Elias Zerhouni argues in Disease Knows No Politics that American biomedical strength depends on a political compact now under strain: science can survive political fights only if evidence, peer review, civil-service independence, immigrant talent, and patient trust remain protected. Drawing on his path from Algeria to Johns Hopkins and the NIH, he warns that separate decisions on funding, universities, immigration, drug pricing, and grant rules can combine to weaken the research system that made the United States a biomedical leader.
At an Aspen Ideas: Health panel, Supreme Court advocates Kannon Shanmugam and Jeffrey Fisher, with moderator Margot Sanger-Katz, argued that some of the term’s most consequential health effects are emerging from cases not formally about health care. Disputes over mifepristone, Roundup labels, conversion therapy, birthright citizenship and gun restrictions show the court reallocating power among presidents, agencies, states, juries, doctors and Congress. Their through-line was institutional: when elected branches leave major health questions unresolved, courts increasingly decide who has authority to set the rules.
At Aspen Ideas: Health, Arianna Huffington, preventive neurologist Richard Isaacson and Bristol Myers Squibb executive Wendy Bartie argued that brain health should be treated as a lifelong continuum, not a late-life dementia problem or a separate mental-health category. Their case was that earlier risk detection, specific daily interventions such as sleep, exercise and nutrition, new medicines, and less fragmented systems of care need to work together. Bartie put the access test bluntly: innovation matters only if people can actually reach it.
National Academy of Medicine president Victor Dzau and pediatrician Lisa Patel argue that health care’s climate responsibility extends beyond greener buildings to the disease burden, supply chains, procurement, care delivery and community resilience that determine the sector’s footprint. In this Aspen Ideas: Health discussion, they frame climate change as both a growing source of illness and a test of whether hospitals, clinicians and suppliers can make emissions accountability as routine as patient safety.
Vercel chief executive Guillermo Rauch used a Stanford MS&E435 seminar to argue that coding agents are expanding the software market rather than merely making developers faster. In his view, AI is widening software creation from professional programmers to business users and autonomous agents, while shifting cloud demand from websites and applications toward deployed agents that need token routing, sandboxes, security, observability and long-running compute.
At Aspen Ideas: Health, Supreme Court litigators Kannon Shanmugam and Jeffrey Fisher argued that major healthcare disputes before the courts are also fights over institutional authority. In cases involving mifepristone, Roundup, conversion therapy, marijuana and firearms, birthright citizenship, disability services, and vaccine mandates, they framed the central question as who gets the final say when health policy reaches judges: agencies, states, juries, Congress, the president, or the Court itself.
GameStop chief executive Ryan Cohen is pitching a $56bn bid for eBay as an operating turnaround rather than a financial trade. In an All-In interview, Cohen argues that eBay’s marketplace remains valuable but has been mismanaged through weak growth, rising costs and damaged seller relationships, and says GameStop could cut $2bn in expenses while expanding eBay into live commerce and digital in-game collectibles. The fight, in his telling, is over whether eBay shareholders trust incumbent management or an owner-operator offering half cash, half GameStop stock.